Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069558 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL13828301 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL12338470 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL13828333 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL10070124 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL12338454 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL10069552 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL12338462 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL10069547 | 1.00 | CDA (0.59) | CDAMAPT | |
| SCHEMBL13828342 | 1.00 | CDA (0.59) | CDAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567363-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567363-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-8951987-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8951987-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | EISAI INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | EISAI INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8268800-B2 | Certain compounds, compositions and methods | EISAI INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2447272-A1 | 2'-Fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors | Eisai Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009052287-A1 | 2 ' -FLU0R0-2 ' -DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAL CORPORATION OF NORTH AMERICA (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | CDA 134/4885MAPT 1627/4885 |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | DUT, TYMP, DPYD | CDA 134/4885MAPT 1627/4885 |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | CDA 134/4885MAPT 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.